Eradication of disease – the case study of polio

Barry D Schoub

Launched in October 1988 by the 41st World Health Assembly (WHA Resolution 41.28), the Global Polio Eradication Initiative aimed to eradicate poliomyelitis from the planet by the year 2000. It is the largest international public health initiative ever undertaken, costing several billion dollars and immunising billions of children worldwide. It has also been mired in controversy almost since its outset.

Coming soon after the euphoria of the smallpox eradication triumph (Fig. 1), the greatest achievement in public health in the 20th century, polio became the next logical vaccine-preventable disease to be targeted for eradication, even though the proposal was not without its detractors, including many of the most prominent public health authorities, some directly involved in the smallpox eradication.

The initial target date, 2000, unfortunately came and went without eradication in sight. So too did the next scheduled date of 2005 (a target set by Rotary International, the most important non-governmental supporter of the Global Polio Eradication Initiative). As yet no future target date has been set. Campaign fatigue has now become a further setback, particularly in the remaining endemic countries such as India where children are now being concealed from the immunisation teams. In another endemic country, Nigeria, politically motivated rumours which surfaced in 2003, alleging that the polio vaccine was maliciously adulterated with contraceptive drugs, led to a catastrophic resurgence of polio in that country and subsequent export of the virus to 20 other countries.

The feasibility of the eradication of polio is again under serious question.

Eradication

Infectious agents that are eradicable are those where the chain of transmission can be broken by an intervention such as a vaccine and where there is no reservoir such as chronic or persistent infection or a non-human host (Fig. 2). Vaccines are theoretically able to successively control, eliminate and eradicate these diseases (Table I).

Executive Director, National Institute for Communicable Diseases; Professor of Virology and Communicable Disease Surveillance

Barry D Schoub, MB BCh, MMed, MD, DSc, FRCPath, FCPath (SA), FRSSAf

Corresponding author: B D Schoub (barrys@nicd.ac.za)
Smallpox, the only disease so far to be eradicated, complied admirably with the requirements of an eradicable disease (Table II).

Undoubtedly the eradication of polio will be far more difficult. What polio shares with smallpox is the availability of a highly effective and cheap vaccine and a virus restricted in nature to humans, with chronic persistent infections occurring only very rarely (discussed below). In contrast to smallpox, what complicates polio eradication is the much greater difficulty in recognition of infection, as the great majority (>99%) of infections are asymptomatic, greatly complicating surveillance and monitoring. The geopolitical climate with multiple conflicts throughout the world, compared with the Cold War smallpox era with relatively few open conflicts, has also greatly hindered polio immunisation efforts.

The strategy, as with smallpox, aims to achieve maximum vaccine coverage to terminate the circulation of the virus in the population coupled with a reliable surveillance tool for the detection of remaining pockets of virus circulation and to monitor progress. Herd immunity is achieved with high routine vaccine coverage (at least 90% for all 3 doses) supplemented by mass immunisation programmes (immunising all infants under 5 years of age independently of the routine immunisation programme on a single day or few days) and mop-up immunisation (house-to-house visits to reach infants missed in the mass immunisation campaign). Syndromic surveillance for acute flaccid paralysis (AFP), the most characteristic clinical presentation of polio, is used as an indicator of virus circulation.

**What has been achieved so far?**

In the two decades of the eradication initiative the incidence of polio has been drastically reduced by over 99%. It was estimated that there were over 350,000 cases of polio in 125 countries in 1988 compared with 2003 when, with improved surveillance, only 784 cases were reported in 6 countries. (Unfortunately there has been a resurgence over the past 3 years – 1,255 cases in 2004, 1,979 cases in 2005 and 1,996 cases in 2006, mainly as a result of the suspension of immunisation programmes in Northern Nigeria in 2003.) Both polio vaccines, trivalent inactivated polio vaccine (TIPV) and trivalent oral polio vaccine (TOPV) using a live attenuated strain of poliovirus termed Sabin-like virus, have proven to be among the most successful human vaccines. The majority of the world’s population now live in countries certified by the World Health Organization as being polio-free – the Americas in 1994, the Western Pacific Region in 2000 and the European Region in 2002. It would also appear that type 2 poliovirus has probably already been eradicated from the world – the last case was reported in 1999. Up to 30 May 2007, 183 wild-type polio cases had been reported globally, less than half of the 453 cases reported for 2006 at the same date. In 2006 polio was confirmed in 17 countries, 94% (1,808 cases) in the 4 endemic countries of Nigeria, India, Pakistan and Afghanistan. (An endemic country is defined as one where the circulation has never been interrupted.) The worst affected country, Nigeria, was responsible for 56% of all cases (1,123) in 2006, followed by India with 34% (674). From these endemic countries, also referred to as reservoir countries, polio was exported to 13 countries where collectively 128 cases (6%) were reported in 2006.

**What still remains to ‘finish the job’?**

Strategies differ somewhat for the endemic/reservoir countries as for the imported countries. In the imported countries polio has been relatively easy to eliminate with multiple rounds of mass immunisation. For example, the type 1 polio outbreak in Namibia in 2006 was fully controlled and eliminated within 60 days. Similarly the large outbreaks in 2005 in Indonesia and Yemen, with 303 and 478 cases respectively, were followed by only 2 cases and 1 case respectively in 2006. The situation in the endemic countries, however, is considerably more complicated. In Afghanistan and Northern Pakistan conflicts have hindered immunisation teams. However, the two main problematic regions in the world are the northern states of Nigeria and Uttar Pradesh and Bihar states in India. Nigeria,

---

**Table I. Epidemiological modification of infectious diseases by vaccination**

<table>
<thead>
<tr>
<th>Level 1: Control</th>
<th>Organism present in population</th>
<th>Surveillance</th>
<th>Vaccination programmes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 2: Elimination</td>
<td>Only imported cases and perhaps a restricted number of contacts</td>
<td>Required</td>
<td>Required</td>
</tr>
<tr>
<td>Level 3: Eradication</td>
<td>No – not present worldwide</td>
<td>Not required</td>
<td>Not required</td>
</tr>
</tbody>
</table>

**Table II. Smallpox: Factors favouring eradication**

- Severe disease – high mortality and sequelae
- No animal reservoir
- Very few subclinical cases
- Cases infectious only at onset of rash
- Recurrence of infectivity never occurred
- Only one serotype
- Effective, stable vaccine
- Success of earlier elimination efforts
- Favourable socio-political factors

November 2007, Vol. 97, No. 11 SAMJ
which is still suffering the legacy of the 2003 suspension of polio immunisation, is the worst affected country in the world with multiple lineages of type 1 virus and also type 3 virus circulating in the population. There has however been considerable improvement in 2007 – 68 cases to date for 2007 compared with 245 to the same date in 2006.\textsuperscript{11} Unfortunately the situation appears to have deteriorated in India, with 44 cases up to 8 May compared with 26 to the same date in 2006, partly due to falling immunisation coverage in parts of Uttar Pradesh and Bihar because of growing parental resistance. Even more problematic here has been the difficulty in achieving successful immunisation, even with multiple rounds of vaccination, because of very high population density, crowding and high levels of diarrhoeal disease interfering with the immunogenicity of TOPV.\textsuperscript{12} Fortunately, recent studies in Uttar Pradesh using high-potency monovalent type 1 polio vaccine, mOPV1, have demonstrated a protective efficacy about 3 times that of TOPV and have raised hopes that multiple rounds (7 - 8) of mOPV1 as well as mOPV3, as appropriate, may be effective in eliminating transmission in this difficult region.\textsuperscript{18}

\textbf{Post-eradication planning}

With the eradication goal-line on the horizon, planning for the post-eradication era is well underway and a number of significant problems and difficulties will need to be addressed, some of which were not envisaged at the commencement of the initiative.\textsuperscript{17-19} The ultimate aim of eradication, as currently defined, is to be able ultimately to dispense with control measures such as vaccination, as was the case with smallpox. Unfortunately, lessons from the successful smallpox eradication provide less guidance for the polio eradication initiative. Stopping polio vaccination in the future will have awesome implications and there would need to be convincing assurance that the virus would not reappear before such a momentous decision is taken. The risk could take the form of either wild-type virus escaping from a facility or vaccine-derived polioviruses. Accidental escape of wild-type virus has indeed already occurred. For example, in 2006, partly due to falling immunisation coverage in parts of Uttar Pradesh and Bihar because of growing parental resistance, 44 cases were reported up to 8 May compared with 26 to the same date in 2006.

Reappearance of poliovirus could also be due to virus derived from OPV.\textsuperscript{22,23} Although the risk of paralytic polio from the vaccine virus is 10 000 times less than for wild-type virus, 1 in 2 million for vaccine virus as against 1 in 200 for wild-type virus, it was this minute risk of vaccine-associated paralytic poliomyelitis (VAPP) that motivated most countries in the developed world to switch from TOPV to TIPV for routine immunisation. Being a live RNA virus, Sabin-like virus mutates in the gastrointestinal tract and in doing so may undergo phenotypic changes including the potential for acquiring neurovirulence and transmissibility. Poliovirus, both wild-type and Sabin-like virus, generally produce acute self-limiting infections of the gastrointestinal tract and do not cause chronic infections with persistent excretion of virus. Sabin-like viruses are normally not isolated from the stool beyond 1 month after receipt of vaccine. Conventionally vaccine viruses that have mutated but still have less than 1% nucleotide sequence changes from the original parental vaccine strain in the VP1 gene are classified as Sabin-like viruses. Those with more than 1% change are termed VDPV (vaccine-derived poliovirus). If Sabin-like virus is provided with opportunities to multiply beyond a month after receiving vaccine it could generate these neurovируlent and transmissible mutational changes. These opportunities could occur in children with primary humoral immunodeficiency, a rare inherited disorder, who may be unable to clear the Sabin-like virus and persistently excrete it for months to years. To date only 31 such cases have been described worldwide, almost all in developed countries. It is deemed unlikely that such cases would survive in developing countries because of the long-term expense of maintenance therapy. Cell-mediated immunodeficiency, such as caused by HIV, does not result in persistent excretion. These viruses are termed iVDPV (immunodeficient vaccine-derived poliovirus).

Secondly, opportunities for mutational change may occur when the virus is able to circulate between the gastrointestinal tracts of susceptible persons in populations where the wild-type virus has been eliminated but vaccination rates have fallen, resulting in populations highly susceptible to infection. In this situation Sabin-like virus often also recombines with type C enteroviruses in the gut, ultimately acquiring phenotypic characteristics of neurovirulence and transmissibility equivalent to those of the wild-type virus. To date, 8 outbreaks due to this transmissible neurovirus mutant, termed eVDPV (circulating vaccine-derived poliovirus), have been described on three continents causing over 100 cases of paralytic polio and involving all three types of poliovirus.\textsuperscript{22,25} The third VDPV, aVDPV (ambigious vaccine-derived poliovirus) refers to VDPV isolates incidentally detected by surveillance of environmental sites where the immune status of the virus excretor is unknown.

The remaining questions

Undoubtedly, the final push to eradication will be by far the hardest. The polio eradication initiative is soon to enter its 3rd decade, a far cry from the 10 years that it took for smallpox...
to be eradicated. One of the most serious challenges that currently confront the polio eradication initiative is to sustain the impetus of the initiative, in particular in competition with enormously pressing competing health needs and especially in the face of the doubts and scepticism. In essence, can polio be eradicated and should polio be eradicated?

**Can polio be eradicated?**

In the remaining pre-eradication phase, what is, in reality, left to address is the main remnant endemic reservoir pockets of Northern Nigeria and Uttar Pradesh and Bihar states of India. Nigeria has certainly made significant progress since the 2003 setback with less than half reported cases in 2007 compared with 2006 up to the same date in May, although India has unfortunately deteriorated from 2006 to 2007 (33 - 55 as of 30 May), although promising data from recent trials of mOPV1 in Uttar Pradesh state may give cause for optimism for this rather intractable region.

More complex is the post-eradication phase and, specifically, the risk of wild-type virus escape and VDPV emergence. Several strategies are planned. A global survey of laboratories that have stored wild-type virus, or materials which potentially could contain wild-type virus, is underway throughout the world. Once completed, laboratories will be segregated into two categories – the risk elimination category and the risk management category. The former, comprising most laboratories in the world, will destroy all material potentially containing wild-type poliovirus. The few laboratories in the risk management category will need to keep material only under regularly supervised bio-safety level-3 containment. Similarly, vaccine manufacturing plants using wild-type virus to produce TIPV will need to propagate the virus under regularly supervised bio-safety level-3 containment. The few laboratories in the world, will destroy all material potentially containing wild-type poliovirus. The few laboratories in the risk management category will need to keep material only under regularly supervised bio-safety level-3 containment.

Surveillance forms a major component of the eradication campaign. A laboratory network co-ordinated by the WHO and consisting of over 125 laboratories throughout the world has been established and is organised in three levels – national laboratories for virus isolation and preliminary characterisation, regional reference laboratories for confirmation and more specialised testing and specialist laboratories. In the post-eradication era laboratory surveillance will necessarily have to continue for many years if not indefinitely as long as the virus is still present in laboratories.

When eradication finally arrives, most countries in the world which are TOPV users will have the option of either going ‘cold turkey’ or switching to TIPV. The ‘cold turkey’ option refers to a synchronous cessation of TOPV where all countries would co-ordinate a global mass immunisation day or few days and then permanently cease the use of TOPV. This is essential to avoid ongoing use of TOPV in some countries that could endanger neighbouring countries who stopped TOPV and who would therefore be vulnerable to cVDPV. The WHO has planned for a stockpile of over 2 billion doses of OPV which could be rushed to a potential hotspot should polio reappear in any part of the world in the post-eradication era.

**Should polio be eradicated?**

Many countries in the developed world are unlikely to cease immunisation in the post-eradication era because of the fear that the disease will recur either from accidental or deliberate wild-type virus release or from VDPV. Using OPV from the stockpile to deal with any possible future outbreak carries its own risks (‘fighting fire with fire’), potentially creating the very conditions that give rise to cVDPV, i.e. introducing OPV into a susceptible population. Careful planning would indeed be required should a vaccine response be needed to stamp out a future re-emerging polio focus to ensure that the remedial campaign is short and sharp, possibly combining TOPV with TIPV administered to surrounding contacts.

The eradication initiative has been criticised for diverting precious and limited financial and human resources away from primary health care needs. Financially, however, a world free of the need for polio vaccine would benefit by saving US$1.5 billion per year in immunisation costs alone, which could be passed on to other health care needs. The alternative option, that of controlling polio at a lower level, which relies on routine immunisation rather than the more intense eradication initiative, has been shown in a recent modelling study to potentially result in greater cumulative costs and a far larger number of cases.

At least as important as the cost-benefit is the enormous value in sensitising the general public to the benefits of immunisation and in the mobilisation of hundreds of thousands of volunteers who could subsequently be motivated for other primary health care needs in a future polio-free world. Another valuable spin-off of the eradication initiative has been the creation of the network of polio laboratories worldwide which are already being utilised for other programmes which require laboratory support, for example measles.

**Are other diseases eradicable in the future?**

A polio eradication success would have the enormous benefit of demonstrating that smallpox eradication was not a one-off event and that disease eradication is conceptually realistic. Measles, in theory, could potentially be targeted for eradication. Its only natural host is humans, persistent excretion does not occur, it is preventable by a highly effective vaccine and it has already been eliminated from several regions of the world. As yet there are no serious plans to undertake a measles eradication initiative, although targets have been set for eliminating measles from several regions in the world.
What will now need to change is not to discard the concept of eradication of disease because of the unforeseen difficulties in the polio eradication initiative, but rather that the definition of eradication may need to be revised. Recent concerns about smallpox reappearing as a biological weapon have shown that even with that relatively easily eradicable disease the need for vaccine has reappeared. With polio many developed countries will not cease immunising their citizens with TIPV even well after the virus has been eradicated for fear of accidental or deliberate reappearance of the virus. Eradication could be re-defined as the absence of evidence of the presence of an organism in the human population, but omitting any reference to cessation of control measures or cessation of surveillance. Another further theoretical category could now be added, that of extinction, which would indicate the permanent and absolute absence of an organism from the planet so that control measures could confidently be permanently stopped. It is highly doubtful whether this stage could be reached with any infectious organism.

References